Zhang Wenhong claims that second-generation sequencing is sufficient for detecting the Nipah virus.

According to reporters, currently there are dozens of institutions nationwide with the ability to detect Nipah virus, mainly concentrated in provincial CDCs and a few large hospitals, with limited identification capabilities at grassroots medical institutions. The above-mentioned experts stated that due to the lack of reported Nipah virus confirmed cases in the country, China lacks clinical treatment experience, with hospitals lacking practical experience in providing respiratory support for severe patients and handling complications in the nervous system. Regarding China's detection capabilities for Nipah virus, Professor Zhang Wenhong, director of the Department of Infectious Diseases at the National Center for Infectious Diseases and affiliated with Huashan Hospital of Fudan University, said, "There is no problem with second-generation sequencing detection capabilities." Currently, second-generation sequencing has become a revolutionary tool for dealing with high-risk pathogens such as Nipah virus, not only for rapid diagnosis and tracing during outbreaks, but also for long-term monitoring of virus evolution, assessing public health risks, and guiding medical strategies.